Psychedelic highlights | April 19 – 23

Shares :

Psychedelic highlights | April 19 – 23

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

MindMedMMED$4.42+ 45.4 %
Psyched WellnessPSYC$0.34+ 36 %
Red Light HollandsTRIP$0.35+ 22.8 %
NuminusNUMI$1.08+ 20 %
Mind CureMCUR$0.42+ 10.5 %
Revive TherapeuticsRVV$0.45+ 4.6 %
M2Bio SciencesWUHN$0.73+ 4.2 %
CompassCMPS$35.30+ 2.7 %
Cybin Inc. CYBN$1.59– 8 %
Field TripFTRP$5.50– 8.6 %

Story of the week

1. Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application [news release]

Revive Therapeutics announce the successful completion of the research results and filing of a U.S. provisional patent application with The United States Patent and Trademark Office (“USPTO”) on an oral thin-film (“OTF”) delivery system with psilocybin developed under a research partnership agreement (“Research study”) with Reed Research Group at the University of Wisconsin-Madison.

Read the full news HERE

2. MindMed To Commence Trading on Nasdaq [news release]

MindMed Inc. announced today that the Company’s subordinate voting shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”).

Read the full news HERE

3. MINDCURE Partners its iSTRYM Technology with LUCID and Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors[news release]

Mind Cure announce a partnership with LUCID Inc.  and announce the hiring of Michael Wolfe as the company’s new Chief Financial Officer. and has named Larissa Chaikowsky to its Board of Directors.

Read the full news HERE

4. M2Bio Sciences (Wuhan General Group) Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility [news release]

M2Bio Sciences announce on the occasion of ‘420 Day’ or ‘Weed Day’ that the company, through its local subsidiary, Tsime Pharmaceuticals and Medicinal Supplies, has started recruiting its team for the rollout of a world class medicinal cannabis cultivation facility.

Read the full article HERE

5. Champignon Brands Announces Revocation of Cease Trade Orders [news release]

Champignon Brands Inc.  announce that the British Columbia Securities Commission and Ontario Securities Commission (the “Commissions”) have revoked their cease trade orders against the Company effective April 22, 2021.  

Read the full article HERE

6. Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction and Establishes Clinical Advisory Board of Renowned Physicians [news release]

Cybin announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction.

And more, Cybin announced the formation of its Clinical Advisory Board, with the additions of Maurizio Fava, MD, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital; Lynn Marie Morski, MD, Esq., President of the Psychedelic Medicine Association; and Anthony Back, MD, Professor in the Department of Medicine and Division of Oncology at the University of Washington. 

Read the full news HERE

7. Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT [news release]

Core One Labs  announce its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has initiated the engineering and design of a proprietary enzymatic production system for the manufacturing of API-grade N,N-dimethyltryptamine (DMT). DMT, a naturally occurring psychedelic substance, is currently under clinical investigation for the treatment of certain mood disorders. 

Read the full news HERE

8. Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific Advisory Board [news release]

Lobe Sciences announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Read the full news HERE

9. Nova Mentis Organizes Autism Data Bank in North America [news release]

Nova Mentis Life Science Corp. announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to support the Company’s development of psilocybin-based compounds in the diagnosis and treatment of ASD.

Read the full news HERE

10. Tryp Therapeutics Reports on Key Milestones for 2021 [news release]

Tryp Therapeutics reported on the Company’s significant progress since successfully completing its Initial Public Offering in December 2020.

Read the full news HERE

11. PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease [news release]

PharmaTher Inc. announced it submitted an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of low-dose ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (“LID-PD”).

Read the full news HERE

12. Red Light Holland Increases Points of Sale for iMicrodose Packs in the Netherlands by More Than 140% [news release]

Red Light Holland’s engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to provide an update on the distribution of its iMicrodose Packs in the Netherlands.

Read the full news HERE

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

Shares :